Sertraline Hydrochloride Tablet
Product Images NDC 50090-7691

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sertraline Hydrochloride (NDC 50090-7691). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907691)

Packaging label for SERTRALINE HYDROCHLORIDE 50 mg oral tablets by A-S Medication Solutions. The label includes product and lot numbers, storage instructions to keep at 20 to 25 degrees Celsius, and indicates a package count of 30 tablets. The label also refers to the film-coated tablets containing sertraline hydrochloride USP equivalent to 50 mg of sertraline.*

FDA Label Image

Image Description (Struct)

Chemical structure of sertraline hydrochloride, the active ingredient in SERTRALINE HYDROCHLORIDE 50 mg oral tablets by A-S Medication Solutions. The image shows the molecular structure including the hydrochloride (HCl) component.*

FDA Label Image

Table 3 (Table 3)

A data table titled 'Common Adverse Reactions in Pooled Placebo-Controlled Trials in Adults with MDD, OCD, PD, PTSD, SAD, and PMDD' comparing percentage incidence of adverse reactions for sertraline hydrochloride (N=3066) versus placebo (N=2293). The table categorizes reactions by system disorders like cardiac, eye, gastrointestinal, nervous system, psychiatric, reproductive, and skin disorders with associated percentages for each group.*

FDA Label Image

Table1 (Table1)

A table presenting the recommended daily dosage of sertraline hydrochloride for patients with MDD, OCD, PD, PTSD, and SAD. It lists starting doses for adults and pediatric patients with indications and includes the therapeutic dose range of 50-200 mg for certain conditions.*

FDA Label Image

Table2 (Table2)

A data table titled 'Table 2: Risk Differences of the Number of Cases of Suicidal Thoughts or Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients.' It presents age ranges alongside drug-placebo differences in the number of patients with suicidal thoughts or behaviors per 1000 patients treated, showing increases compared to placebo for ages under 18 and 18-24, and decreases for ages 25-64 and 65 or older.*

FDA Label Image

Image Description (Table4)

A data table presenting the most common sexual adverse reactions occurring in 2% or more of patients and at least twice the placebo rate. The table compares sertraline hydrochloride to placebo in men and women with depression and related disorders, listing conditions such as ejaculation failure, decreased libido, erectile dysfunction, ejaculation disorder, and male sexual dysfunction.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.